The YODA Project Research Proposal Due Diligence Assessment

Part 1: General Information		
YODA Project (Protocol) ID:	2023-5290	
Date:	28 July 2023	
Product Name:	Abiraterone	
Therapeutic Area:	Oncology	
Product Class:	Hormones/Nonsteroidal antiandrogen	
Condition(s) Studied:	Prostate Cancer	
Protocol Number(s) and Title(s):	A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) (NCT01715285) Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer (NCT00887198) Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy (NCT00638690)	
Part 2: Data Availability		
Data Holder has authority to	provide clinical trial data or development partner	Yes
has agreed to share clinical trial data.		
Comments:		
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.		Yes
Comments:		
De-identification and redaction of clinical trial data in accordance with current		Yes
HIPAA and EU criteria allows protection of participant privacy and		
confidentiality.		
Comments:		
The product and relevant indication studied has either been approved by		Yes
regulators in the US and EU, or terminated from development. Comments:		
Data Holder has completed the clinical trial and trial has been completed for a Yes		
period of at least 18 months (or results published in peer-reviewed		
biomedical literature).	, , , , , , , , , , , , , , , , , , , ,	
Comments:		
Part 3: Data Availability Summary		
Based on the responses to the above Data Availability questions, the Yes		
requested clinical trial data are available for a data sharing request.		163
Part 4: Proposal Review		
Question:		Response:
Summary-level CSR data is appropriate for the proposed analysis.		No
Participant-level data is appropriate for the proposed analysis.		Yes
A similar analysis is underway or completed/pending disclosure by Janssen.		No

The YODA Project Research Proposal Due Diligence Assessment